Cytogenetic studies in ovarian cancer

Jacqueline Whang-Peng, Turid Knutsen, Edwin C. Douglass, Elizabeth Chu, Robert F. Ozols, W. Michael Hogan, Robert C. Young

Research output: Contribution to journalArticle

134 Citations (Scopus)

Abstract

Cytogenetic studies of ovarian cancer have been conducted in the Medicine Branch, NCI, National Institutes of Health for 5 years. A total of 72 patients were studied by direct preparation and/or 1- to 3-day short-term culture of ascites (86 samples), pleural fluid (4 samples), and tumor (2 samples). Repeat examinations (1-24 months later) were performed in 7 of the 72 patients. Forty-four patients (62%) were successfully analyzed with banding techniques: 6 patients had adenocarcinoma, 7 had serous adenocarcinoma, 13 had serous papillary adenocarcinoma, 7 had serous papillary cystadenocarcinoma, 2 had mucinous adenocarcinoma, 6 had undifferentiated or poorly differentiated adenocarcinoma, 1 had clear cell adenocarcinoma, and 2 were not classified. Of these 44 patients, 29 had received prior chemotherapy, 14 were untreated, and in 1 patient the treatment status was unknown. Aneuploidy was observed in all patients and there was considerable variation in the chromosome numbers (even within single samples), often ranging from diploidy to triploidy to tetraploidy. All 44 patients had numerical abnormalities and 39 had structural abnormalities. The chromosomes most frequently involved in structural abnormalities (in decreasing order according to the number of patients involved) were #1, #3, #2, #4, #9, #10, #15, #19, #6, and #11; the least involved chromosomes were #21 and #5. Clone formation and the number of chromosomes involved in structural abnormalities increased with duration of disease and were more extensive in patients treated with chemotherapy than in patients treated with surgery alone. Our data did not show a deletion of chromosome #6 (6q-) to be specific for ovarian cancer.

Original languageEnglish
Pages (from-to)91-106
Number of pages16
JournalCancer Genetics and Cytogenetics
Volume11
Issue number1
DOIs
Publication statusPublished - Jan 1 1984
Externally publishedYes

Fingerprint

Cytogenetics
Ovarian Neoplasms
Adenocarcinoma
Chromosomes
Papillary Cystadenocarcinoma
Serous Cystadenocarcinoma
Clear Cell Adenocarcinoma
Papillary Adenocarcinoma
Drug Therapy
Triploidy
Mucinous Adenocarcinoma
Chromosomes, Human, Pair 21
Chromosomes, Human, Pair 6
Tetraploidy
National Institutes of Health (U.S.)
Aneuploidy
Diploidy
Ascites
Clone Cells
Medicine

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Whang-Peng, J., Knutsen, T., Douglass, E. C., Chu, E., Ozols, R. F., Michael Hogan, W., & Young, R. C. (1984). Cytogenetic studies in ovarian cancer. Cancer Genetics and Cytogenetics, 11(1), 91-106. https://doi.org/10.1016/0165-4608(84)90102-X

Cytogenetic studies in ovarian cancer. / Whang-Peng, Jacqueline; Knutsen, Turid; Douglass, Edwin C.; Chu, Elizabeth; Ozols, Robert F.; Michael Hogan, W.; Young, Robert C.

In: Cancer Genetics and Cytogenetics, Vol. 11, No. 1, 01.01.1984, p. 91-106.

Research output: Contribution to journalArticle

Whang-Peng, J, Knutsen, T, Douglass, EC, Chu, E, Ozols, RF, Michael Hogan, W & Young, RC 1984, 'Cytogenetic studies in ovarian cancer', Cancer Genetics and Cytogenetics, vol. 11, no. 1, pp. 91-106. https://doi.org/10.1016/0165-4608(84)90102-X
Whang-Peng J, Knutsen T, Douglass EC, Chu E, Ozols RF, Michael Hogan W et al. Cytogenetic studies in ovarian cancer. Cancer Genetics and Cytogenetics. 1984 Jan 1;11(1):91-106. https://doi.org/10.1016/0165-4608(84)90102-X
Whang-Peng, Jacqueline ; Knutsen, Turid ; Douglass, Edwin C. ; Chu, Elizabeth ; Ozols, Robert F. ; Michael Hogan, W. ; Young, Robert C. / Cytogenetic studies in ovarian cancer. In: Cancer Genetics and Cytogenetics. 1984 ; Vol. 11, No. 1. pp. 91-106.
@article{d675b112fbc64b018496910786bdf7b4,
title = "Cytogenetic studies in ovarian cancer",
abstract = "Cytogenetic studies of ovarian cancer have been conducted in the Medicine Branch, NCI, National Institutes of Health for 5 years. A total of 72 patients were studied by direct preparation and/or 1- to 3-day short-term culture of ascites (86 samples), pleural fluid (4 samples), and tumor (2 samples). Repeat examinations (1-24 months later) were performed in 7 of the 72 patients. Forty-four patients (62{\%}) were successfully analyzed with banding techniques: 6 patients had adenocarcinoma, 7 had serous adenocarcinoma, 13 had serous papillary adenocarcinoma, 7 had serous papillary cystadenocarcinoma, 2 had mucinous adenocarcinoma, 6 had undifferentiated or poorly differentiated adenocarcinoma, 1 had clear cell adenocarcinoma, and 2 were not classified. Of these 44 patients, 29 had received prior chemotherapy, 14 were untreated, and in 1 patient the treatment status was unknown. Aneuploidy was observed in all patients and there was considerable variation in the chromosome numbers (even within single samples), often ranging from diploidy to triploidy to tetraploidy. All 44 patients had numerical abnormalities and 39 had structural abnormalities. The chromosomes most frequently involved in structural abnormalities (in decreasing order according to the number of patients involved) were #1, #3, #2, #4, #9, #10, #15, #19, #6, and #11; the least involved chromosomes were #21 and #5. Clone formation and the number of chromosomes involved in structural abnormalities increased with duration of disease and were more extensive in patients treated with chemotherapy than in patients treated with surgery alone. Our data did not show a deletion of chromosome #6 (6q-) to be specific for ovarian cancer.",
author = "Jacqueline Whang-Peng and Turid Knutsen and Douglass, {Edwin C.} and Elizabeth Chu and Ozols, {Robert F.} and {Michael Hogan}, W. and Young, {Robert C.}",
year = "1984",
month = "1",
day = "1",
doi = "10.1016/0165-4608(84)90102-X",
language = "English",
volume = "11",
pages = "91--106",
journal = "Cancer Genetics and Cytogenetics",
issn = "0165-4608",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Cytogenetic studies in ovarian cancer

AU - Whang-Peng, Jacqueline

AU - Knutsen, Turid

AU - Douglass, Edwin C.

AU - Chu, Elizabeth

AU - Ozols, Robert F.

AU - Michael Hogan, W.

AU - Young, Robert C.

PY - 1984/1/1

Y1 - 1984/1/1

N2 - Cytogenetic studies of ovarian cancer have been conducted in the Medicine Branch, NCI, National Institutes of Health for 5 years. A total of 72 patients were studied by direct preparation and/or 1- to 3-day short-term culture of ascites (86 samples), pleural fluid (4 samples), and tumor (2 samples). Repeat examinations (1-24 months later) were performed in 7 of the 72 patients. Forty-four patients (62%) were successfully analyzed with banding techniques: 6 patients had adenocarcinoma, 7 had serous adenocarcinoma, 13 had serous papillary adenocarcinoma, 7 had serous papillary cystadenocarcinoma, 2 had mucinous adenocarcinoma, 6 had undifferentiated or poorly differentiated adenocarcinoma, 1 had clear cell adenocarcinoma, and 2 were not classified. Of these 44 patients, 29 had received prior chemotherapy, 14 were untreated, and in 1 patient the treatment status was unknown. Aneuploidy was observed in all patients and there was considerable variation in the chromosome numbers (even within single samples), often ranging from diploidy to triploidy to tetraploidy. All 44 patients had numerical abnormalities and 39 had structural abnormalities. The chromosomes most frequently involved in structural abnormalities (in decreasing order according to the number of patients involved) were #1, #3, #2, #4, #9, #10, #15, #19, #6, and #11; the least involved chromosomes were #21 and #5. Clone formation and the number of chromosomes involved in structural abnormalities increased with duration of disease and were more extensive in patients treated with chemotherapy than in patients treated with surgery alone. Our data did not show a deletion of chromosome #6 (6q-) to be specific for ovarian cancer.

AB - Cytogenetic studies of ovarian cancer have been conducted in the Medicine Branch, NCI, National Institutes of Health for 5 years. A total of 72 patients were studied by direct preparation and/or 1- to 3-day short-term culture of ascites (86 samples), pleural fluid (4 samples), and tumor (2 samples). Repeat examinations (1-24 months later) were performed in 7 of the 72 patients. Forty-four patients (62%) were successfully analyzed with banding techniques: 6 patients had adenocarcinoma, 7 had serous adenocarcinoma, 13 had serous papillary adenocarcinoma, 7 had serous papillary cystadenocarcinoma, 2 had mucinous adenocarcinoma, 6 had undifferentiated or poorly differentiated adenocarcinoma, 1 had clear cell adenocarcinoma, and 2 were not classified. Of these 44 patients, 29 had received prior chemotherapy, 14 were untreated, and in 1 patient the treatment status was unknown. Aneuploidy was observed in all patients and there was considerable variation in the chromosome numbers (even within single samples), often ranging from diploidy to triploidy to tetraploidy. All 44 patients had numerical abnormalities and 39 had structural abnormalities. The chromosomes most frequently involved in structural abnormalities (in decreasing order according to the number of patients involved) were #1, #3, #2, #4, #9, #10, #15, #19, #6, and #11; the least involved chromosomes were #21 and #5. Clone formation and the number of chromosomes involved in structural abnormalities increased with duration of disease and were more extensive in patients treated with chemotherapy than in patients treated with surgery alone. Our data did not show a deletion of chromosome #6 (6q-) to be specific for ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=0021368199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021368199&partnerID=8YFLogxK

U2 - 10.1016/0165-4608(84)90102-X

DO - 10.1016/0165-4608(84)90102-X

M3 - Article

C2 - 6690026

AN - SCOPUS:0021368199

VL - 11

SP - 91

EP - 106

JO - Cancer Genetics and Cytogenetics

JF - Cancer Genetics and Cytogenetics

SN - 0165-4608

IS - 1

ER -